

Client: Example Client ABC123  
123 Test Drive  
Salt Lake City, UT 84108  
UNITED STATES

Physician: Doctor, Example

**Patient: Patient, Example**

**DOB:** Unknown  
**Gender:** Unknown  
**Patient Identifiers:** 01234567890ABCD, 012345  
**Visit Number (FIN):** 01234567890ABCD  
**Collection Date:** 00/00/0000 00:00

**Rheumatoid Arthritis (RA) Panel**

ARUP test code 3016634

Rheumatoid Factor **20 IU/mL H (Ref Interval: 0-14)**

Carbamylated Protein Antibody, IgG **25 Units H (Ref Interval: 0-19)**

INTERPRETIVE INFORMATION: Carbamylated Protein (CarP) Ab, IgG  
Anti-carbamylated protein (anti-CarP) IgG antibodies are present in about 34-53 percent of patients with RA, have specificities of greater than 90 percent and can occur in RA patients seronegative for both rheumatoid factor and anti-CCP. These autoantibodies may be present in the preclinical phase of disease, are associated with future RA development, and may predict radiographic joint destruction. Patients with weak positive results should be monitored and testing repeated.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Cyclic Citrullinated Peptide Ab, IgG/A **40 Units H (Ref Interval: 0-19)**

INTERPRETIVE INFORMATION: Cyclic Citrullinated Peptide Ab, IgG/A

19 Units or less ..... Negative  
20-39 Units ..... Weak Positive  
40-59 Units ..... Moderate Positive  
60 Units or greater ..... Strong Positive

A positive result for cyclic citrullinated peptide (CCP) antibodies in conjunction with consistent clinical features may be suggestive of rheumatoid arthritis (RA). Anti-CCP, IgG/IgA antibodies are present in about 66-74 percent of RA patients and have specificities of 96-99 percent. Detection of IgA antibodies in addition to the usual IgG antibodies enhances the sensitivity due to some RA patients having IgA antibodies to CCP in the absence of IgG. These autoantibodies may be present in the preclinical phase of disease, are associated with future RA development, and may predict radiographic joint destruction. Patients with weak positive results should be monitored and testing repeated.

**H=High, L=Low, \*=Abnormal, C=Critical**

Unless otherwise indicated, testing performed at:

VERIFIED/REPORTED DATES

Procedure	Accession	Collected	Received	Verified/Reported
Rheumatoid Factor	23-240-121260	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Carbamylated Protein Antibody, IgG	23-240-121260	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Cyclic Citrullinated Peptide Ab, IgG/A	23-240-121260	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00

END OF CHART

H=High, L=Low, \*=Abnormal, C=Critical

*Unless otherwise indicated, testing performed at:*

ARUP LABORATORIES | 800-522-2787 | aruplab.com  
500 Chipeta Way, Salt Lake City, UT 84108-1221  
Jonathan R. Genzen, MD, PhD, Laboratory Director

Patient: Patient, Example  
ARUP Accession: 23-240-121260  
Patient Identifiers: 01234567890ABCD, 012345  
Visit Number (FIN): 01234567890ABCD  
Page 2 of 2 | Printed: 8/29/2023 7:29:52 AM  
4848